Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 42

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 42
---
 2024:

|                                                            |     |           |     |    |     | Number of securities to be issued upon exercise of outstanding options, warrants and rights 
 (a)                                                                                         | Weighted-average exercise price of outstanding options, warrants and rights 
 ($)(1)                                                                      |     |       |     |            |     |    |     | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 
 (#)                                                                                                                                         |
| Plan Category                                              |     |           |     |    |     |                                                                                             |                                                                             |     |       |     |            |     |    |     |                                                                                                                                             |
| Equity compensation plans approved by security holders     |     | 5,751,819 |     | -2 |     |                                                                                             |                                                                             |     | 25.20 |     | 10,022,973 |     | -3 |     |                                                                                                                                             |
| Equity compensation plans not approved by security holders |     |         — |     |    |     |                                                                                             |                                                                             |     |     — |     |          — |     |    |     |                                                                                                                                             |
| Total                                                      |     | 5,751,819 |     |    |     |                                                                                             |                                                                             |     | 25.20 |     | 10,022,973 |     |    |     |                                                                                                                                             |

(1) The weighted-average exercise price does not reflect the shares that will be issued in connection with the settlement of performance stock units and restricted stock units, since such units have no exercise price.

(2) Excludes purchase rights accruing under the ESPP.

(3) Consists of 8,971,566 shares available for issuance under our 2023 Plan, and 1,051,407 shares available for purchase under our ESPP.

Required Vote

The approval of the Plan Amendment will be determined by the vote of a majority of the shares present at the Annual Meeting or voting by proxy and entitled to vote at the Annual Meeting. Abstentions will have the same effect as votes “AGAINST” this proposal. Broker non-votes will have no effect on this proposal as they are not considered entitled to vote for the foregoing purpose. This proposal is considered to be a non-routine proposal on which a broker or other nominee does not have discretionary authority to vote.

| The Board of Directors recommends a vote“FOR”the approval of the Amendment to the Veracyte, Inc. 2023